Fennec Pharmaceuticals Inc. (FENC)
| Market Cap | 361.54M+11.8% |
| Revenue (ttm) | 59.22M |
| Net Income | -3.25M |
| EPS | -0.12 |
| Shares Out | 35.07M |
| PE Ratio | n/a |
| Forward PE | 10.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 583 |
| Open | 10.31 |
| Previous Close | 10.36 |
| Day's Range | 10.31 - 10.31 |
| 52-Week Range | 5.65 - 13.25 |
| Beta | 1.23 |
| Analysts | Strong Buy |
| Price Target | 17.67(+71.35%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About FENC
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$FENC stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in FENC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by FENC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
FENC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New FENC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to FENC from public contracts
Source: USAspending.gov
FENC Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from FENC’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score